Cipla

Sep 22, 2016

Collaboration between Sygnis AG and ECACC for licensing and distribution of Caco-2 cell line Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis' Caco-2 business. Under the collaboration, ECACC will organize that companies obtain the license for the use of the Caco-2 cell line f...

Sep 07, 2016

Targeted treatment can become a reality for esophageal cancer, as a study opens door A group of researchers Scientists, funded by Cancer Research UK and Medical Research Council, have discovered that oesophageal cancer can be classified into three different subtypes, paving the way for testing targeted treatments ta...